Literature DB >> 25501125

Molecular pathways: aspirin and Wnt signaling-a molecularly targeted approach to cancer prevention and treatment.

Manish K Gala1, Andrew T Chan2.   

Abstract

The anti-inflammatory properties of aspirin have resulted in its widespread use as an analgesic, antipyretic, and cardioprotective agent. Beyond these applications, multiple observational studies and randomized controlled trials have demonstrated a chemopreventative role for aspirin, particularly in the development of colorectal neoplasia. Given the critical importance of Wnt dysregulation in colorectal carcinogenesis, the interplay between aspirin and canonical Wnt signaling has become a focus of investigation. These studies have illuminated our understanding of the anticancer mechanisms of aspirin, yielding the identification of potential biomarkers for which aspirin's chemopreventative efficacy can be safely optimized into routine clinical practice and providing leads into the discovery of novel preventive and therapeutic targets. In this review, we summarize key experimental and clinical studies of this interaction, as well as highlighting future strategies to advance their clinical translation. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25501125      PMCID: PMC4383688          DOI: 10.1158/1078-0432.CCR-14-0877

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  57 in total

1.  Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A.

Authors:  C L Bos; L L Kodach; G R van den Brink; S H Diks; M M van Santen; D J Richel; M P Peppelenbosch; J C H Hardwick
Journal:  Oncogene       Date:  2006-07-31       Impact factor: 9.867

2.  The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling.

Authors:  Sari Tuupanen; Mikko Turunen; Rainer Lehtonen; Outi Hallikas; Sakari Vanharanta; Teemu Kivioja; Mikael Björklund; Gonghong Wei; Jian Yan; Iina Niittymäki; Jukka-Pekka Mecklin; Heikki Järvinen; Ari Ristimäki; Mariachiara Di-Bernardo; Phil East; Luis Carvajal-Carmona; Richard S Houlston; Ian Tomlinson; Kimmo Palin; Esko Ukkonen; Auli Karhu; Jussi Taipale; Lauri A Aaltonen
Journal:  Nat Genet       Date:  2009-06-28       Impact factor: 38.330

3.  A randomized trial of aspirin to prevent colorectal adenomas.

Authors:  John A Baron; Bernard F Cole; Robert S Sandler; Robert W Haile; Dennis Ahnen; Robert Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Michael Beach; Gerald J Beck; John H Bond; Tim Byers; E Robert Greenberg; Jack S Mandel; Norman Marcon; Leila A Mott; Loretta Pearson; Fred Saibil; Rosalind U van Stolk
Journal:  N Engl J Med       Date:  2003-03-06       Impact factor: 91.245

4.  Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis.

Authors:  K Watanabe; T Kawamori; S Nakatsugi; T Ohta; S Ohuchida; H Yamamoto; T Maruyama; K Kondo; F Ushikubi; S Narumiya; T Sugimura; K Wakabayashi
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

5.  TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells.

Authors:  Dianne M Heijink; Mathilde Jalving; Dorenda Oosterhuis; Ineke A Sloots; Roelof Koster; Harry Hollema; Jan H Kleibeuker; Jan J Koornstra; Elisabeth G E de Vries; Steven de Jong
Journal:  J Pathol       Date:  2010-10-29       Impact factor: 7.996

6.  Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice.

Authors:  P C Chulada; M B Thompson; J F Mahler; C M Doyle; B W Gaul; C Lee; H F Tiano; S G Morham; O Smithies; R Langenbach
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

7.  Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant {beta}-Catenin Activation in Colon Cancer.

Authors:  Snehal Naik; Robin S Dothager; Jayne Marasa; Cory L Lewis; David Piwnica-Worms
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

8.  APC mutations occur early during colorectal tumorigenesis.

Authors:  S M Powell; N Zilz; Y Beazer-Barclay; T M Bryan; S R Hamilton; S N Thibodeau; B Vogelstein; K W Kinzler
Journal:  Nature       Date:  1992-09-17       Impact factor: 49.962

9.  Aspirin and the risk of colorectal cancer in women.

Authors:  E Giovannucci; K M Egan; D J Hunter; M J Stampfer; G A Colditz; W C Willett; F E Speizer
Journal:  N Engl J Med       Date:  1995-09-07       Impact factor: 91.245

10.  Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells.

Authors:  Oksana Voloshanenko; Gerrit Erdmann; Taronish D Dubash; Iris Augustin; Marie Metzig; Giusi Moffa; Christian Hundsrucker; Grainne Kerr; Thomas Sandmann; Benedikt Anchang; Kubilay Demir; Christina Boehm; Svenja Leible; Claudia R Ball; Hanno Glimm; Rainer Spang; Michael Boutros
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  29 in total

1.  Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma.

Authors:  Altaf Mohammed; Naveena B Janakiram; Venkateshwar Madka; Yuting Zhang; Anil Singh; Laura Biddick; Qian Li; Stanley Lightfoot; Vernon E Steele; Ronald A Lubet; Chen S Suen; Mark Steven Miller; Shizuko Sei; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2019-09-17

2.  Cooperative antiproliferative signaling by aspirin and indole-3-carbinol targets microphthalmia-associated transcription factor gene expression and promoter activity in human melanoma cells.

Authors:  Kevin M Poindexter; Susanne Matthew; Ida Aronchik; Gary L Firestone
Journal:  Cell Biol Toxicol       Date:  2016-04-07       Impact factor: 6.691

3.  Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants.

Authors:  Hongmei Nan; Carolyn M Hutter; Yi Lin; Eric J Jacobs; Cornelia M Ulrich; Emily White; John A Baron; Sonja I Berndt; Hermann Brenner; Katja Butterbach; Bette J Caan; Peter T Campbell; Christopher S Carlson; Graham Casey; Jenny Chang-Claude; Stephen J Chanock; Michelle Cotterchio; David Duggan; Jane C Figueiredo; Charles S Fuchs; Edward L Giovannucci; Jian Gong; Robert W Haile; Tabitha A Harrison; Richard B Hayes; Michael Hoffmeister; John L Hopper; Thomas J Hudson; Mark A Jenkins; Shuo Jiao; Noralane M Lindor; Mathieu Lemire; Loic Le Marchand; Polly A Newcomb; Shuji Ogino; Bethann M Pflugeisen; John D Potter; Conghui Qu; Stephanie A Rosse; Anja Rudolph; Robert E Schoen; Fredrick R Schumacher; Daniela Seminara; Martha L Slattery; Stephen N Thibodeau; Fridtjof Thomas; Mark Thornquist; Greg S Warnick; Brent W Zanke; W James Gauderman; Ulrike Peters; Li Hsu; Andrew T Chan
Journal:  JAMA       Date:  2015-03-17       Impact factor: 56.272

Review 4.  Carpe low-dose aspirin: the new anti-cancer face of an old anti-platelet drug.

Authors:  Annachiara Mitrugno; Joanna L Sylman; Rachel A Rigg; Samuel Tassi Yunga; Joseph J Shatzel; Craig D Williams; Owen J T McCarty
Journal:  Platelets       Date:  2017-12-21       Impact factor: 3.862

5.  Aspirin use and the risk of cholangiocarcinoma.

Authors:  Jonggi Choi; Hassan M Ghoz; Thoetchai Peeraphatdit; Esha Baichoo; Benyam D Addissie; William S Harmsen; Terry M Therneau; Janet E Olson; Roongruedee Chaiteerakij; Lewis R Roberts
Journal:  Hepatology       Date:  2016-04-26       Impact factor: 17.425

6.  Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer.

Authors:  Yin Cao; Reiko Nishihara; Kana Wu; Molin Wang; Shuji Ogino; Walter C Willett; Donna Spiegelman; Charles S Fuchs; Edward L Giovannucci; Andrew T Chan
Journal:  JAMA Oncol       Date:  2016-06-01       Impact factor: 31.777

7.  Metabolomics Analysis of Aspirin's Effects in Human Colon Tissue and Associations with Adenoma Risk.

Authors:  Elizabeth L Barry; Veronika Fedirko; Karan Uppal; Chunyu Ma; Ken Liu; Leila A Mott; Janet L Peacock; Michael N Passarelli; John A Baron; Dean P Jones
Journal:  Cancer Prev Res (Phila)       Date:  2020-07-12

8.  Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin.

Authors:  Hemant K Roy; Vladimir Turzhitsky; Ramesh Wali; Andrew J Radosevich; Borko Jovanovic; Gary Della'Zanna; Asad Umar; David T Rubin; Michael J Goldberg; Laura Bianchi; Mart De La Cruz; Andrej Bogojevic; Irene B Helenowski; Luz Rodriguez; Robert Chatterton; Silvia Skripkauskas; Katherine Page; Christopher R Weber; Xiaoke Huang; Ellen Richmond; Raymond C Bergan; Vadim Backman
Journal:  Gut       Date:  2015-10-26       Impact factor: 23.059

9.  A comprehensive in vivo and mathematic modeling-based kinetic characterization for aspirin-induced chemoprevention in colorectal cancer.

Authors:  Tadanobu Shimura; Shusuke Toden; Natalia L Komarova; Crichard Boland; Dominik Wodarz; Ajay Goel
Journal:  Carcinogenesis       Date:  2020-07-10       Impact factor: 4.944

10.  Transcriptome-wide In Vitro Effects of Aspirin on Patient-derived Normal Colon Organoids.

Authors:  Matthew A M Devall; David A Drew; Christopher H Dampier; Sarah J Plummer; Stephen Eaton; Jennifer Bryant; Virginia Díez-Obrero; Jiancheng Mo; Dmitriy Kedrin; Dylan C Zerjav; Oliver Takacsi-Nagy; Lucas T Jennelle; Mourad W Ali; Ömer H Yilmaz; Victor Moreno; Steven M Powell; Andrew T Chan; Ulrike Peters; Graham Casey
Journal:  Cancer Prev Res (Phila)       Date:  2021-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.